RNF43 and colorectal cancer: A clinical trial of the peptide vaccines RNF43 and TOMM34 combined with chemotherapy for stage III colorectal cancer revealed that patients with a positive CTL response showed good 3-year relapse-free survival regardless of HLA-A*2402 status (22).